Spectral AI Q4 net income $0.6M; FY 2025 revenue $19.7M; guides 2026 revenue ~$18.5M

Spectral AI, Inc.

Q4 2025 net income $0.6M ($0.02 diluted EPS) vs net loss ($7.7M) in Q4 2024.
FY 2025 net loss narrowed to ($7.6M) from ($15.3M); R&D revenue $19.7M (down from $29.6M).
Cash at Dec 31, 2025 rose to $15.4M from $5.2M at Dec 31, 2024.
Received additional $31.7M BARDA funding; total BARDA contract up to $150M; De Novo 510(k) submitted for DeepView burn indication.
2026 revenue guidance ~$18.5M, primarily from BARDA contract; no material product sales expected.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spectral AI, Inc. reported Year ending December 31, 2026 results: revenue $18.5 million. Guidance initiated.

Period: Year ending December 31, 2026
Revenue: $18.5 million
Guidance: initiated
Result: guidance update

Exact text from the filing

The Company is forecasting revenue of approximately $18.5 million for the year ending December 31, 2026, primarily reflecting the continued development of the Company’s DeepView System through the BARDA PBS Contract. This guidance does not include any material contributions from the sale of the DeepView System for the burn indication.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spectral AI, Inc. reported Fourth Quarter and Full Year ended December 31, 2025 results: revenue Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 Million, net income Net income for Q4 2025 was $0.6 million; Net loss for FY 2025 was $(7.6) million, EPS Q4 2025: $0.02 per diluted share; FY 2025: $(0.29) per diluted share.

Period: Fourth Quarter and Full Year ended December 31, 2025
Revenue: Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 Million
Net income: Net income for Q4 2025 was $0.6 million; Net loss for FY 2025 was $(7.6) million
EPS: Q4 2025: $0.02 per diluted share; FY 2025: $(0.29) per diluted share
Result: reported results

Exact text from the filing

Research & Development Revenue Research & Development revenue for Q4 2025 was $3.8 million compared to $7.6 million, reflecting the anticipated reduction in research direct labor, clinical trial and other reimbursed study costs relative to 2024 as the Company moved closer to completion of the base phase of its contract with BARDA (the “BARDA PBS Contract”). Research & Development Revenue for FY 2025 decreased to $19.7 million from $29.6 million, reflecting the anticipated overall reduction in the Company’s reimbursed costs associated with the BARDA PBS Contract during 2025 following the Company’s submission of its De Novo application to the FDA. Gross Margin Gross margin for Q4 2025 was 39.8% compared to 44.0% due primarily to a lower percentage of reimbursed direct labor as a component of overall revenue from the BARDA PBS Contract. Gross margin for FY 2025 was 45.4% compared to 44.9%, reflecting a consistent mix of direct labor as a percentage of the total work performed on the BARDA

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Spectral AI, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-034047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.